Cabot Top Ten Trader guides growth investors and investment professionals to the strongest stocks in the market—the stocks that are attracting big institutional money and could be starting a long-term uptrend.
Top Ten stocks are screened for both short-term and long-term relative strength, as well as current market environment, company fundamentals and an attractive entry point on the chart.
The average Top Ten stock has outperformed the market by nearly 15 percentage points since 2007.
Sign up now for a risk-free trial subscription to Cabot Top Ten Trader. Try Cabot Top Ten Trader for 60 days.
With Cabot Top Ten Trader as your guide, you'll invest with the pros, following the big institutions into the market's strongest stocks.
Why Is Cabot Top Ten Trader Right For You?
Uncover the hottest momentum stocks across all sectors-- the stocks the big institutions are buying!
Take advantage of stocks that can offer both short-term and long-term success!
With specific buy ranges and suggested stop-loss ranges, you’ll have an immediate plan for each stock.
Our Top Ten Market Timing System is designed to put you in position to maximize market upside while protecting on the downside.
Diversify your portfolio with the hottest stocks from all market sectors.
Beat the market by 15 percentage points with a strategy that individuals and investment professionals have used since 2002.
Whenever you have questions, chief analyst Michael Cintolo is just an email away.
Our 45 years of investment experience puts you in good hands.
Join Cabot Top Ten Trader risk-free for 60 days—if it’s not for you, cancel and receive a full refund.
See Returns Like These:
213.52% in Carmax
63% in Bluebird Bio
75% in Pharmacyclics
60% in Freescale Semiconductor
Try Cabot Top Ten Trader for 60 days. If you don’t like it, you don’t pay.
What our Customers say about Cabot Top Ten Trader
I recently recommended Cabot Top Ten to my son-in-law. Here’s what I wrote: We are into a two-year subscription with Cabot Top Ten. Nice easy PDF format with ten stocks weekly emailed Monday eve and one chosen as Editor’s Choice (Mike Cintolo). Market condition and buy ranges. Finds leaders at and before major breakouts. Fundamental and technical condition. Overall company prospects (speculative play, industry leader/competition). Former recommendations updated with hold, buy, sell. Update sent out Friday after market. We have done very well and took some gains, a few small losses and hold some big gains.
Robert R., Bethesda, Maryland
It is the very best—most readable, most understandable, most helpful, most thorough, most "user-friendly"—report there could ever be. Often when its recommendations have soared, it has felt positively magical—it is so thrilling to be led to such amazing stocks. In a good market, its recommendations have often produced profits beyond my imagination. And as part of it all are Mike's responses and suggestions—from which I have learned SO MUCH and thanks to which I've preserved profits I might otherwise have lost. If there were only one report on earth, this would be my choice. It's just the way I like to invest—seeing a relatively immediate growth rather than having to wait for years. And more than any other report, it is just so much FUN and so utterly engaging to follow it. I cannot praise it enough—or express my gratitude sufficiently
S. Sherman, Riverdale, New York
If Cabot Market Letter is like driving a safe and luxurious Lexus, Cabot Top Ten is like a Ferrari loaded with stocks that set their own speed limits. I have been a long-term Cabot Market Letter fan and enjoy reading market conditions, commentary, momentum stocks, tip of the month and stock picks. Recently, I subscribed to Cabot Top Ten and I enjoy reading it. Top Ten picks are really quality stocks that are advancing much faster than regular stocks. I eagerly await this newsletter each Monday. I have been investing in some very profitable securities week after week, taking advantage of the bull market this year.
Nirmal R., San Francisco, California
Are you ready to get started with your risk-free trial subscription?